HC Wainwright reiterated their buy rating on shares of XOMA (NASDAQ:XOMA - Free Report) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $104.00 target price on the biotechnology company's stock. HC Wainwright also issued estimates for XOMA's Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at $0.23 EPS, FY2025 earnings at ($0.29) EPS and FY2026 earnings at $0.12 EPS.
Separately, StockNews.com lowered shares of XOMA from a "hold" rating to a "sell" rating in a research note on Tuesday, February 25th.
Check Out Our Latest Analysis on XOMA
XOMA Stock Down 0.9 %
NASDAQ:XOMA traded down $0.18 during mid-day trading on Wednesday, reaching $20.88. The company's stock had a trading volume of 81,363 shares, compared to its average volume of 26,480. XOMA has a 1 year low of $19.92 and a 1 year high of $35.00. The stock has a fifty day moving average of $24.37 and a 200-day moving average of $27.12. The firm has a market capitalization of $250.12 million, a PE ratio of -6.00 and a beta of 1.00. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28.
XOMA (NASDAQ:XOMA - Get Free Report) last released its quarterly earnings data on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.17). XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The business had revenue of $8.70 million during the quarter, compared to analysts' expectations of $8.75 million. Equities research analysts forecast that XOMA will post -1.41 earnings per share for the current year.
Insiders Place Their Bets
In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the business's stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $26.10, for a total value of $13,069,366.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 7.20% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On XOMA
A number of large investors have recently added to or reduced their stakes in XOMA. Woodline Partners LP raised its holdings in XOMA by 63.9% in the fourth quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company's stock worth $4,107,000 after purchasing an additional 60,927 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of XOMA by 238.9% during the fourth quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company's stock valued at $318,000 after acquiring an additional 8,522 shares in the last quarter. Barclays PLC increased its holdings in shares of XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company's stock valued at $298,000 after acquiring an additional 8,447 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of XOMA during the fourth quarter valued at about $206,000. Finally, Renaissance Technologies LLC increased its holdings in shares of XOMA by 89.8% during the fourth quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company's stock valued at $423,000 after acquiring an additional 7,619 shares in the last quarter. 95.92% of the stock is currently owned by institutional investors.
About XOMA
(
Get Free Report)
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
Further Reading
Before you consider XOMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XOMA wasn't on the list.
While XOMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
